Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Innate Pharma S.A.

    NASDAQ: IPHA · Real-Time Price · USD
    1.85
    -0.02 (-1.07%)
    At close: Jun 17, 2025, 12:28 PM

    Innate Pharma S.A. Statistics

    Share Statistics

    Innate Pharma S.A. has 92.16M shares outstanding. The number of shares has increased by 3.54% in one year.

    Shares Outstanding

    n/a
    		 92.16M

    Shares Change (YoY)

    n/a
    		 3.54%

    Shares Change (QoQ)

    n/a
    		 1.24%

    Owned by Institutions (%)

    n/a
    		 0.17%

    Shares Floating

    n/a
    		 56M

    Failed to Deliver (FTD) Shares

    n/a
    		 107,000

    FTD / Avg. Volume

    n/a
    		 452.76%

    Short Selling Information

    The latest short interest is 56.22K, so 0.06% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 56.22K

    Short % of Shares Out

    n/a
    		 0.06%

    Short % of Float

    n/a
    		 0.07%

    Short Ratio (days to cover)

    n/a
    		 5.28

    Valuation Ratios

    The PE ratio is -2.91 and the forward PE ratio is 7.23. Innate Pharma S.A.'s PEG ratio is -0.01.

    PE Ratio

    n/a
    		 -2.91

    Forward PE

    n/a
    		 7.23

    PS Ratio

    n/a
    		 11.41

    Forward PS

    n/a
    		 1

    PB Ratio

    n/a
    		 16.3

    P/FCF Ratio

    n/a
    		 -19.76

    PEG Ratio

    n/a
    		 -0.01
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Innate Pharma S.A..

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 2.6, with a Debt / Equity ratio of 3.51.

    Current Ratio

    n/a
    		 2.6

    Quick Ratio

    n/a
    		 2.6

    Debt / Equity

    n/a
    		 3.51

    Debt / EBITDA

    n/a
    		 -0.66

    Debt / FCF

    n/a
    		 -4.25

    Interest Coverage

    n/a
    		 -91.12

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 $69,729.28

    Profits Per Employee

    n/a
    		 $-273,320.44

    Employee Count

    n/a
    		 181

    Asset Turnover

    n/a
    		 0.11

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 n/a

    Effective Tax Rate

    n/a
    		 0%

    Stock Price Statistics

    The stock price has increased by -11.9% in the last 52 weeks. The beta is 0.98, so Innate Pharma S.A.'s price volatility has been higher than the market average.

    Beta

    n/a
    		 0.98

    52-Week Price Change

    n/a
    		 -11.9%

    50-Day Moving Average

    n/a
    		 2.07

    200-Day Moving Average

    n/a
    		 1.99

    Relative Strength Index (RSI)

    n/a
    		 31.98

    Average Volume (20 Days)

    n/a
    		 23,633

    Income Statement

    In the last 12 months, Innate Pharma S.A. had revenue of 12.62M and earned -49.47M in profits. Earnings per share was -0.61.

    Revenue

    n/a
    		 12.62M

    Gross Profit

    n/a
    		 12.62M

    Operating Income

    n/a
    		 -51.58M

    Net Income

    n/a
    		 -49.47M

    EBITDA

    n/a
    		 -46.91M

    EBIT

    n/a
    		 -48.91M

    Earnings Per Share (EPS)

    n/a
    		 -0.61
    Full Income Statement

    Balance Sheet

    The company has 66.4M in cash and 31M in debt, giving a net cash position of 35.4M.

    Cash & Cash Equivalents

    n/a
    		 66.4M

    Total Debt

    n/a
    		 31M

    Net Cash

    n/a
    		 35.4M

    Retained Earnings

    n/a
    		 -386.36M

    Total Assets

    n/a
    		 111.06M

    Working Capital

    n/a
    		 52.76M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -6.9M and capital expenditures -391K, giving a free cash flow of -7.29M.

    Operating Cash Flow

    n/a
    		 -6.9M

    Capital Expenditures

    n/a
    		 -391K

    Free Cash Flow

    n/a
    		 -7.29M

    FCF Per Share

    n/a
    		 -0.09
    Full Cash Flow Statement

    Margins

    Gross margin is 100%, with operating and profit margins of -408.64% and -391.97%.

    Gross Margin

    n/a
    		 100%

    Operating Margin

    n/a
    		 -408.64%

    Pretax Margin

    n/a
    		 -391.97%

    Profit Margin

    n/a
    		 -391.97%

    EBITDA Margin

    n/a
    		 -371.69%

    EBIT Margin

    n/a
    		 -408.64%

    FCF Margin

    n/a
    		 -57.74%

    Dividends & Yields

    IPHA does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for IPHA is $11, which is 494.6% higher than the current price. The consensus rating is "Buy".

    Price Target

    n/a
    		 $11

    Price Target Difference

    n/a
    		 494.6%

    Analyst Consensus

    n/a
    		 Buy

    Analyst Count

    n/a
    		 1
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Scores

    Altman Z-Score

    n/a
    		 -4.39

    Piotroski F-Score

    n/a
    		 4

    Add to Watchlist